Mineralys Therapeutics Inc (MLYS)

$23.69 -1.36 (-5.43%)
Market Cap 2.07B
Revenue (ttm) 0.00
Net Income (ttm) -154.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,182,800
Avg Vol 1,423,088
Day's Range N/A - N/A
Shares Out 82.50M
Stochastic %K 4%
Beta 0.57
Analysts Strong Sell
Price Target $48.50

Company Profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name t...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 378 6240
Address:
150 N. Radnor Chester Road, Suite F200, Radnor, United States
Voxxx
Voxxx Jun. 5 at 6:05 PM
$MLYS volume edge...
0 · Reply
roscoe44
roscoe44 Jun. 5 at 5:18 PM
$MLYS starter here.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 5:01 PM
$MLYS Share Price: $23.83 Contract Selected: Dec 18, 2026 $25 Calls Buy Zone: $2.89 – $3.57 Target Zone: $5.44 – $6.65 Potential Upside: 78% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 5 at 4:36 PM
$MLYS Classic pressure to take shares from weak hands. The high volume, especially considering it’s Friday, is a good sign that buying power exists. Once they change direction it will fly. Next week would be fun
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 5 at 2:08 PM
$MLYS Nice resistance on a bearish day ($XBI). Bottom is around $25, the uptrend should start soon pushing it to +$40 as we approach the PDUFA, with a potential BO at $60 per share.
0 · Reply
Diiiii
Diiiii Jun. 5 at 8:47 AM
$MLYS A closer look at the revised Tanabe contract exposes a critical structural signal regarding buyout. The new Change of Control clause triggers an immediate $100M payout upon a buyout. ​Logically, MLYS wouldn't draft this—Tanabe demanded it. By giving up perpetual royalties, Tanabe clearly anticipated a near-term buyout and engineered a hedge to capture the premium. Sell-side analysts speculating about buyout is one thing, but the original lorundrostat developer legally hardcoding a $100M buyout clause is on an entirely different level of conviction. ​The strategic "elephant in the room" is now written in ink.
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 5 at 7:50 AM
$MLYS The market is trying to push it lower before it changes direction. Volume was strong yesterday and resisted the downward pressure. I’m not sure it can go much lower from here. From these levels, there are two major catalysts ahead: FDA approval and a potential buyout. I remind you this quote from Jefferies: “based on analysis of M&A activity over the past 20 years. The firm identified 13 such deals out of 68 total transactions that occurred during review or after PDUFA dates. The firm said acquisition timing typically occurs two to three months before PDUFA when deals happen during the review period.”
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 4 at 5:57 PM
$MLYS Looks like they accumulate before they start the uptrend. It might take a couple of days before it runs back to $30+
1 · Reply
CapitalMonk
CapitalMonk Jun. 4 at 11:00 AM
$MLYS Price: $25.06 (-13.14%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.20% RSI: 43.8 | Momentum: Moderate Volume: +428.6% vs avg Volatility: 5.00% Support: $23.65 | Resistance: $32.14 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 4 at 10:08 AM
$MLYS With $2B+ peak sales potential, acquiring the company while leaving up to 10% royalties in place makes little sense. Over 10 years, that royalty burden could easily exceed $1B. Management just cleaned up that issue for $300M
0 · Reply
Latest News on MLYS
Mineralys Therapeutics falls -17.1%

2026-06-03T16:06:46.000Z - 2 days ago

Mineralys Therapeutics falls -17.1%

Mineralys Therapeutics falls -12.7%

2026-06-03T15:57:06.000Z - 2 days ago

Mineralys Therapeutics falls -12.7%

Mineralys prices offering of 5.66M shares of common stock at $26.50

2026-06-03T15:48:11.000Z - 2 days ago

Mineralys prices offering of 5.66M shares of common stock at $26.50

Mineralys Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:35 AM EDT - 2 days ago

Mineralys Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Mineralys to repurchase future royalty payments in Tanabe license agreement

2026-06-03T10:19:53.000Z - 2 days ago

Mineralys to repurchase future royalty payments in Tanabe license agreement

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Jun 3, 2026, 6:05 AM EDT - 2 days ago

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Jun 3, 2026, 6:00 AM EDT - 2 days ago

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Mineralys Therapeutics presents new data for lorundrostat

2026-05-31T21:05:04.000Z - 5 days ago

Mineralys Therapeutics presents new data for lorundrostat

Mineralys' pill cuts blood pressure in kidney disease patients

May 30, 2026, 11:20 AM EDT - 6 days ago

Mineralys' pill cuts blood pressure in kidney disease patients

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

May 30, 2026, 11:15 AM EDT - 6 days ago

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 27, 2026, 8:00 AM EDT - 9 days ago

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

Mineralys Therapeutics Transcript: AGM 2026

May 21, 2026, 3:30 PM EDT - 15 days ago

Mineralys Therapeutics Transcript: AGM 2026

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

May 18, 2026, 4:05 PM EDT - 18 days ago

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 12:20 PM EDT - 24 days ago

Mineralys Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs

2026-05-07T19:15:38.000Z - 4 weeks ago

Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs

Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)

2026-05-07T00:50:30.000Z - 4 weeks ago

Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)

Mineralys Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2026

Mineralys Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Mineralys Therapeutics Earnings release: Q1 2026

Mineralys Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Mineralys Therapeutics Quarterly report: Q1 2026

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026, 4:05 PM EDT - 4 weeks ago

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics Slides: Corporate presentation

May 6, 2026, 4:00 PM EDT - 4 weeks ago

Mineralys Therapeutics Slides: Corporate presentation

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2026, 5:34 PM EDT - 4 weeks ago

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 5, 2026, 8:00 AM EDT - 4 weeks ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

Apr 29, 2026, 4:05 PM EDT - 5 weeks ago

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

Mineralys Therapeutics initiated with a Buy at TD Cowen

2026-04-27T09:40:39.000Z - 5 weeks ago

Mineralys Therapeutics initiated with a Buy at TD Cowen

Mineralys Therapeutics Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Mineralys Therapeutics Proxy statement: Proxy filing

Mineralys Therapeutics Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Mineralys Therapeutics Proxy statement: Proxy filing

Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board

2026-03-31T11:08:33.000Z - 2 months ago

Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board

IMUX

Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer

2026-03-24T12:11:17.000Z - 2 months ago

Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Mineralys Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Mineralys Therapeutics Slides: Corporate presentation

Mineralys Therapeutics price target raised to $51 from $46 at BofA

2026-03-13T12:12:20.000Z - 3 months ago

Mineralys Therapeutics price target raised to $51 from $46 at BofA

Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)

2026-03-12T20:36:58.000Z - 3 months ago

Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)

Mineralys Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2025

Mineralys Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Annual report: Q4 2025

Mineralys Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Earnings release: Q4 2025

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 4:05 PM EDT - 3 months ago

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA

2026-03-09T20:35:52.000Z - 3 months ago

Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

Jan 6, 2026, 8:00 AM EST - 5 months ago

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

Dec 12, 2025, 11:00 AM EST - 6 months ago

Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

Mineralys Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:25 PM EST - 6 months ago

Mineralys Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Nov 26, 2025, 4:05 PM EST - 6 months ago

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 2:00 PM EST - 7 months ago

Mineralys Therapeutics Transcript: Stifel 2025 Healthcare Conference

Mineralys Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:30 AM EST - 7 months ago

Mineralys Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Mineralys Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2025

Mineralys Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Mineralys Therapeutics Quarterly report: Q3 2025

Mineralys Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Mineralys Therapeutics Earnings release: Q3 2025

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 4:05 PM EST - 7 months ago

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 7 months ago

Mineralys Therapeutics Slides: Corporate Presentation

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Nov 7, 2025, 6:10 PM EST - 7 months ago

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

Oct 21, 2025, 8:00 AM EDT - 8 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

Mineralys Therapeutics Slides: Corporate Presentation

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Mineralys Therapeutics Slides: Corporate Presentation

Mineralys Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 1:30 PM EDT - 8 months ago

Mineralys Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Sep 30, 2025, 8:00 AM EDT - 8 months ago

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Sep 5, 2025, 9:00 AM EDT - 9 months ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 4, 2025, 4:01 PM EDT - 9 months ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Mineralys Therapeutics Slides: Corporate Presentation

Sep 4, 2025, 2:00 AM EDT - 9 months ago

Mineralys Therapeutics Slides: Corporate Presentation

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Sep 2, 2025, 9:33 PM EDT - 9 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Sep 2, 2025, 4:01 PM EDT - 9 months ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Mineralys Therapeutics Earnings Call Transcript: Q2 2025

Mineralys Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Mineralys Therapeutics Quarterly report: Q2 2025

Mineralys Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Mineralys Therapeutics Earnings release: Q2 2025

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 10 months ago

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Aug 4, 2025, 4:05 PM EDT - 10 months ago

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Jun 30, 2025, 11:17 AM EDT - 1 year ago

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Mineralys Therapeutics Transcript: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: Study Result

Mineralys Therapeutics Press release: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Press release: Study Result

Mineralys Therapeutics Slides: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: Study Result

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Mineralys Therapeutics Slides: FY 2025

May 25, 2025, 11:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: FY 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

May 24, 2025, 4:30 AM EDT - 1 year ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

May 20, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

Mineralys Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 7:35 PM EDT - 1 year ago

Mineralys Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Mineralys Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2025

Mineralys Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Quarterly report: Q1 2025

Mineralys Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings release: Q1 2025

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

May 5, 2025, 4:05 PM EDT - 1 year ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Apr 23, 2025, 5:23 PM EDT - 1 year ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mineralys Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Proxy statement: Proxy Filing

Mineralys Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Proxy statement: Proxy Filing

Mineralys Therapeutics Transcript: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: KOL Event

Mineralys Therapeutics Slides: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: KOL Event

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mar 29, 2025, 2:30 PM EDT - 1 year ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 11, 2025, 10:20 PM EDT - 1 year ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Transcript: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: Study Result

Mineralys Therapeutics Press release: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Press release: Study Result

Mineralys Therapeutics Slides: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: Study Result

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:12 AM EDT - 1 year ago

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mar 7, 2025, 4:01 PM EST - 1 year ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mineralys Therapeutics Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2024

Mineralys Therapeutics Annual report: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Annual report: Q4 2024

Mineralys Therapeutics Earnings release: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Earnings release: Q4 2024

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 12, 2025, 7:00 AM EST - 1 year ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Feb 5, 2025, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Mineralys Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 4, 2024, 4:15 PM EST - 1 year ago

Mineralys Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Mineralys Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 10:20 AM EST - 1 year ago

Mineralys Therapeutics Transcript: Stifel 2024 Healthcare Conference

Mineralys Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 4:00 PM EST - 1 year ago

Mineralys Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Mineralys Therapeutics Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2024

Mineralys Therapeutics Quarterly report: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Quarterly report: Q3 2024

Mineralys Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Earnings release: Q3 2024

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Nov 5, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Voxxx
Voxxx Jun. 5 at 6:05 PM
$MLYS volume edge...
0 · Reply
roscoe44
roscoe44 Jun. 5 at 5:18 PM
$MLYS starter here.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 5:01 PM
$MLYS Share Price: $23.83 Contract Selected: Dec 18, 2026 $25 Calls Buy Zone: $2.89 – $3.57 Target Zone: $5.44 – $6.65 Potential Upside: 78% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 5 at 4:36 PM
$MLYS Classic pressure to take shares from weak hands. The high volume, especially considering it’s Friday, is a good sign that buying power exists. Once they change direction it will fly. Next week would be fun
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 5 at 2:08 PM
$MLYS Nice resistance on a bearish day ($XBI). Bottom is around $25, the uptrend should start soon pushing it to +$40 as we approach the PDUFA, with a potential BO at $60 per share.
0 · Reply
Diiiii
Diiiii Jun. 5 at 8:47 AM
$MLYS A closer look at the revised Tanabe contract exposes a critical structural signal regarding buyout. The new Change of Control clause triggers an immediate $100M payout upon a buyout. ​Logically, MLYS wouldn't draft this—Tanabe demanded it. By giving up perpetual royalties, Tanabe clearly anticipated a near-term buyout and engineered a hedge to capture the premium. Sell-side analysts speculating about buyout is one thing, but the original lorundrostat developer legally hardcoding a $100M buyout clause is on an entirely different level of conviction. ​The strategic "elephant in the room" is now written in ink.
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 5 at 7:50 AM
$MLYS The market is trying to push it lower before it changes direction. Volume was strong yesterday and resisted the downward pressure. I’m not sure it can go much lower from here. From these levels, there are two major catalysts ahead: FDA approval and a potential buyout. I remind you this quote from Jefferies: “based on analysis of M&A activity over the past 20 years. The firm identified 13 such deals out of 68 total transactions that occurred during review or after PDUFA dates. The firm said acquisition timing typically occurs two to three months before PDUFA when deals happen during the review period.”
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 4 at 5:57 PM
$MLYS Looks like they accumulate before they start the uptrend. It might take a couple of days before it runs back to $30+
1 · Reply
CapitalMonk
CapitalMonk Jun. 4 at 11:00 AM
$MLYS Price: $25.06 (-13.14%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.20% RSI: 43.8 | Momentum: Moderate Volume: +428.6% vs avg Volatility: 5.00% Support: $23.65 | Resistance: $32.14 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 4 at 10:08 AM
$MLYS With $2B+ peak sales potential, acquiring the company while leaving up to 10% royalties in place makes little sense. Over 10 years, that royalty burden could easily exceed $1B. Management just cleaned up that issue for $300M
0 · Reply
Diiiii
Diiiii Jun. 3 at 10:53 PM
$MLYS For megapharma other than AZN, highly necessary drug for obtaining just before approval. Institutional investors hold over 100% of the outstanding shares (even considering the newly issued shares). Groundbreaking announcements were made at the recent ESH meeting. I think it was a great time to buy. https://youtu.be/aQmZw0jYT7s
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 3 at 6:12 PM
$MLYS The chances of acquisition have risen significantly after today’s news. This is a small company with no commercial experience. Does anyone really think they would dilute, spend $200M cash and take debt to buy back mid-single-digit royalties, up to 10%, before approval? Absolutely not. This looks like a classic pre-M&A move: the buyer wants the whole package clean, without royalties, while $MLYS needs to show strength and be well funded in case the deal isn’t finalized.
0 · Reply
notreload_ai
notreload_ai Jun. 3 at 5:15 PM
$MLYS raised cash via $150M stock sale, $500M loan, and $200M royalty buyout to fund drug ahead of FDA decision; stock fell. https://notreload.xyz/xy/mineralys-strikes-150m-deal-500m-loan-buys-out-royalties/
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 3 at 4:38 PM
$MLYS This company will be bougth at around $50 per share in the next 4-5 months
1 · Reply
Doozio
Doozio Jun. 3 at 4:38 PM
$MLYS become $GRRR zzzzz????
0 · Reply
Machiaveltrade
Machiaveltrade Jun. 3 at 4:20 PM
$MLYS major position for me here !! Opportunity!!!
0 · Reply
BiotechButterflies
BiotechButterflies Jun. 3 at 4:14 PM
$MLYS ... confused... whats the catch?
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 3 at 3:56 PM
$MLYS Added more 🥹
0 · Reply
Diiiii
Diiiii Jun. 3 at 2:15 PM
$MLYS The drop to below $24 earlier might have been a once-in-a-lifetime buying opportunity. Clean up licensing rights at this time is clearly a positive move. It could be a "tidying up of affairs" before a big deal.
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 3 at 1:53 PM
$MLYS Buying back royalties before approval looks like classic pre-M&A cleanup.
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 3 at 1:49 PM
$MLYS WOW.. This is a MEGA BUY. Added here a big chunk
0 · Reply
Diiiii
Diiiii Jun. 3 at 1:07 PM
$MLYS I couldn't include today's offering in the content, but I've put together a YouTube video summarizing the events leading up to ESH. Please use it as one of the factors to consider before "buying the dip." https://youtu.be/aQmZw0jYT7s
0 · Reply